Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
U.S. FDA grants approval to market tamoxifen oral liquid for breast cancer
December 1st, 2005
Savient Pharmaceuticals, Inc. (SVNTE) announced that the U.S. Food and Drug Administration (FDA) has approved its new drug application (NDA) for Soltamox (tamoxifen oral solution) for the treatment of breast cancer in adjuvant and metastatic settings and to reduce risks of breast cancer in women with ductal carcinoma in situ (DCIS) and reduction of breast cancer incidence in women with high risk of breast cancer. Soltamox is the product of Savient's wholly owned subsidiary, Rosemont Pharmaceuticals Ltd. located in Leeds, U.K. Soltamox represents the first oral liquid product entry into the U.S. from Savient's wholly owned U.K. subsidiary and it will...
Source: Women's Health Weekly (2005-12-01)
|
